Creating a Genetic Testing Specialty Under CLIA: What Are We Waiting For?

Nov 29, 2005

Since the inception of the Human Genome Project in 1990, genetic testing has become an increasingly integral component in the diagnosis, treatment, management, and prevention of numerous diseases and conditions. Today, the number of genetic tests available is rising dramatically, with new tests entering the healthcare market every day. Information gained from genetic test results has a significant impact on medical decision-making. Incorrect genetic test results can lead to misdiagnosis, inappropriate and/or delayed treatment, anxiety, and, in rare cases, even death. While there are many diligent laboratories that comply with voluntary measures to ensure quality, the absence of oversight creates an environment in which poor performers can continue in the marketplace and bad actors can go undetected and uncensored. From the doctor and patient’s perspective, moreover, the minimalist level of regulation makes it difficult to distinguish high quality from low quality laboratories. As the role of genetic testing in medicine continues to grow, so too does the urgent need to ensure that the genetic tests offered to the public are accurate and reliable and provide information relevant to a patient’s current or future health status.

Read the full report Creating a Genetic Testing Specialty Under CLIA: What Are We Waiting For? on the Genetics & Public Policy Center's Web site.

Pew is no longer active in this line of work, but for more information, visit the Genetics & Public Policy Center Web site or visit theGenetics and Public Policy Centeron   

(All Fields are required)